BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sarno G, Montalti R, Giglio MC, Rompianesi G, Tomassini F, Scarpellini E, De Simone G, De Palma GD, Troisi RI. Hepatocellular carcinoma in patients with chronic renal disease: Challenges of interventional treatment. Surg Oncol 2021;36:42-50. [PMID: 33307490 DOI: 10.1016/j.suronc.2020.11.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Shirazian S, Starakiewicz P, Latcha S. Cancer Screening in End-Stage Kidney Disease. Advances in Chronic Kidney Disease 2021;28:502-508.e1. [DOI: 10.1053/j.ackd.2021.09.006] [Reference Citation Analysis]
2 Abdel-hamid NM, Abass SA, Eldomany RA, Abdel-kareem MA, Zakaria S. Dual regulating of mitochondrial fusion and Timp-3 by leflunomide and diallyl disulfide combination suppresses diethylnitrosamine-induced hepatocellular tumorigenesis in rats. Life Sciences 2022;294:120369. [DOI: 10.1016/j.lfs.2022.120369] [Reference Citation Analysis]
3 Yeh H, Chiang CC, Yen TH. Hepatocellular carcinoma in patients with renal dysfunction: Pathophysiology, prognosis, and treatment challenges. World J Gastroenterol 2021; 27(26): 4104-4142 [PMID: 34326614 DOI: 10.3748/wjg.v27.i26.4104] [Reference Citation Analysis]
4 Fabrizi F, Cerutti R, Alfieri CM, Ridruejo E. An Update on Hepatocellular Carcinoma in Chronic Kidney Disease. Cancers (Basel) 2021;13:3617. [PMID: 34298832 DOI: 10.3390/cancers13143617] [Reference Citation Analysis]